Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
December 10th 2023Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.
Read More
Dr Bal on the Investigation of BMS-986393 in R/R Multiple Myeloma
June 21st 2023Susan Bal, MD, discusses updated safety and efficacy data from the dose-escalation and dose-expansion portions of phase 1 trial of the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in patients with relapsed/refractory multiple myeloma.
Read More